Is AbbVie Inc. (ABBV) the Best Pharma Stock to Buy for Long Term Growth?
We recently published a list of . In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best pharma stocks to buy for long term growth.
With big American pharmaceutical corporations always searching for medications in China, the US pharmaceutical industry is going through a unique trend never seen before. About 30% of Big Pharma acquisitions involving at least $50 million upfront in 2024 involved Chinese corporations, according to DealForma statistics, as reported by CNBC. This was an increase from 20% the previous year and nearly 0% just five years before.
Experts cite several causes for this tendency. Some people think that Chinese pharmaceutical firms are drawing notice due to their sophisticated development skills, which enable them to produce potent compounds in large quantities. In addition to being able to start testing on human subjects more quickly, these Chinese companies can charge a lower price for these medications than the US. Buyers have developed a business strategy that enables them to import medicines through licensing agreements, according to CNBC. The dearth of venture capital in China is additional pressure on biotech companies to enter these agreements.
Experts think this situation is here to stay, even though there are several possible causes for this tendency. Although the US pharmaceutical industry is expected to be impacted, it is uncertain how these effects would manifest. If big pharmaceutical companies find a good Chinese drug at a low price, some experts think it may destroy American startups; others think the competition would benefit the sector. Tim Opler, a managing director in Stifel's global healthcare group, stated the following regarding the circumstances:
'It's kind of a watershed moment where the pharma industry is like, 'We don't really need to buy U.S. biotechs necessarily. We will if it makes sense, but we can buy perfectly good biotech assets through licensing deals with Chinese companies.'
Emily Field, Head of European Pharma Research at Barclays, spoke to CNBC on February 20 about the performance of obesity medications, the effects of US tariffs, and the dynamics of the pharmaceutical industry. According to her, at least in the first half of this year, the industry might not perform poorly. The effectiveness of obesity medications is still up for debate, though, as leading companies in the field have shown inconsistent results in the past.
Speaking about the tariffs, she stated that since some businesses assemble their products in the US after producing them overseas, their implementation raises several unanswered questions for the pharmaceutical industry. These businesses, therefore, have relatively low manufacturing costs, which is an important factor to take into account when assessing the effects of tariffs. She thought that these businesses could easily absorb the higher expense of the tariffs. The topic hasn't come up much on earnings calls this quarter, and the market is nearing the end of the reporting season.
For this article, we screened for companies that operate in the pharmaceutical industry. From that list, we identified stocks that have achieved positive revenue growth over the past five years. Then, we picked companies with a 5-year revenue growth of 10% and ranked the top 10 based on hedge fund sentiment as of Q4 2024, as per Insider Monkey's database.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist.
Number of Hedge Fund Holders: 85
AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions.
In addition to having solid fundamentals, AbbVie Inc. (NYSE:ABBV) made $15.1 billion in fiscal Q4 2024, which was 5.6% higher than analysts had predicted. The company's ex-Humira platform, a group of medications in its pharmaceutical portfolio, was credited with this expansion. The platform increased sales by over 18% throughout the course of the year, and in fiscal Q4 2024, revenue growth accelerated to 22%.
Because of its two popular medications, Skyrizi and Rinvoq, analysts are upbeat about AbbVie Inc. (NYSE:ABBV)'s growth. As one of the best pharmaceutical stocks, the yearly sales of these medications—which treat inflammatory bowel disorders, psoriatic illnesses, rheumatology, and dermatology—are expected to surpass $27 billion by 2027. In addition, the company declared a 5.8% dividend increase that would take effect in February 2025, carrying on the company's 12-year dividend growth pattern.
said the following about AbbVie Inc. (NYSE:ABBV) in its Q3 2024:
'US biopharma/biotech companies topped the health care sector, with the majority of holdings posting returns over 10%. AbbVie Inc. (NYSE:ABBV) showed positive top-line growth from its immunosuppressive drugs, Skyrizi and Rinvoq. Abbvie's management continues to work through the loss of exclusivity from Humira, switching patients to Skyrizi or Rinvoq rather than Humira biosimilars.'
Overall, ABBV ranks 4th on our list of best pharma stocks to buy for long term growth. While we acknowledge the potential of pharmaceutical companies, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ABBV but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
READ NEXT: and .
Disclosure: None. This article is originally published at .
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
16 minutes ago
- Business Wire
CEA Opens Shanghai–Auckland–Buenos Aires "New International Land-Sea Trade Corridor" to First Bridge China and South America
SHANGHAI--(BUSINESS WIRE)--On June 18, 2025, China Eastern Airlines (CEA) and Auckland Airport signed a cooperation agreement in Shanghai. According to the plan, CEA will launch commercial flights in December 2025 from Shanghai Pudong International Airport to Ministro Pistarini International Airport via Auckland Airport. The signing ceremony was attended by government officials, corporate representatives, and heads from relevant departments. New Zealand's Prime Minister Christopher Luxon highlighted that the new route will enhance global connectivity by linking Auckland with the dynamic economies of Asia and South America. He also announced that New Zealand will implement a visa-free transit policy for Chinese travelers passing through Auckland. Since the opening of the route to Auckland in 2014, CEA has shown strong growth. Chairman Wang Zhiqing stated that the airline will leverage its Shanghai hub to accelerate the construction of its global route network. The new route will serve as a vital bridge among New Zealand, China, the Asia-Pacific region, and South America, supporting the Belt and Road Initiative. Auckland Airport expressed satisfaction with the imminent realization of the jointly envisioned " New International Land-Sea Trade Corridor". CEA, Auckland Airport's key partner and now the leading carrier on the China–New Zealand route, has maintained steady operations and consistently expanded capacity. The new service, to be operated twice weekly by Boeing 777, will be the only direct air link between Argentina and China, filling the gap in direct air services between the two nations. The "New International Land-Sea Trade Corridor" shortens travel time by 4–5 hours versus European or North American routes and offers direct flights, while also reducing jet lag—passengers only face a 4-hour time difference when transiting through Auckland, as opposed to 12 hours via traditional Western routes. CEA plans to apply for fifth freedom for this route, enabling passenger and cargo transport in Auckland, boosting economic, trade, and people-to-people exchanges among New Zealand, China, and Argentina. Currently, CEA operates flights from Auckland to both Shanghai Pudong and Hangzhou Xiaoshan. Following the new route launch, CEA will boost New Zealand–China capacity deployment, increasing Auckland–Shanghai flights from 7 to 9 weekly. Note: The new route remains subject to final regulatory approval.
Business Wire
30 minutes ago
- Business Wire
Ares Management Acquires Minority Stake in Plenitude for €2 Billion
LONDON & MILAN--(BUSINESS WIRE)--Ares Management Corporation ('Ares') (NYSE: ARES), a leading global alternative investment manager, announced today that Ares Alternative Credit funds ('Ares Alternative Credit') have entered into a definitive agreement for the acquisition of a 20% stake in Plenitude, a leader in energy transition controlled by Eni, for approximately €2 billion. The consideration implies an enterprise value for Plenitude of over €12 billion. Completion of the transaction is subject to customary regulatory approvals. Plenitude operates in over 15 countries worldwide, integrating a business model that combines over 4 GW of renewable energy production, as well as retail and energy solutions. The company serves more than 10 million customers and manages an extensive network of 21,500 charging points for electric vehicles. 'This transaction underscores the strength of the Ares platform, which leverages experience across its diversified businesses, including asset-based finance and renewables infrastructure, to deliver flexible capital at scale,' said Joel Holsinger, Partner and Co-Head of Alternative Credit at Ares. 'We are excited to support Plenitude as the company executes its growth strategy focused on enduring profitability and positive community impact.' 'Plenitude is an established leader in energy transition, with a differentiated business model and an outstanding track record, and we are delighted to be part of its next phase of growth,' said Stefano Questa, Partner and Co-Head of European Alternative Credit. Stefano Goberti, CEO of Plenitude, said, 'I am pleased to welcome Ares, one of the world's leading investment funds, as a new shareholder in Plenitude. The deal is a further endorsement of the quality of our strategic approach, which combines economic and environmental sustainability in an integrated business model projected on the future of the energy sector. Ares, with its entry into the company, highlights the progression of Plenitude's value and becomes part of our growth journey, which we pursue with determination and conviction day after day.' The Ares Alternative Credit strategy is a leading investor in asset-based finance, managing approximately $42.9 billion in assets under management as of March 31, 2025. The team invests across the capital structure and seeks opportunities in large, diversified portfolios across various sectors, including specialty finance, lender finance, equipment leasing, structured products, net lease, cash flow streams (e.g., royalties, licensing, management fees) and other asset-focused investments. Aligning Ares' investment activities with its social impact, Ares and Ares Alternative Credit portfolio managers have committed to donate a portion of the performance fees from Ares Alternative Credit's Pathfinder family of funds to support global health and education charities. About Ares Management Corporation Ares Management Corporation (NYSE: ARES) is a leading global alternative investment manager offering clients complementary primary and secondary investment solutions across the credit, real estate, private equity and infrastructure asset classes. We seek to provide flexible capital to support businesses and create value for our stakeholders and within our communities. By collaborating across our investment groups, we aim to generate consistent and attractive investment returns throughout market cycles. As of March 31, 2025, Ares Management Corporation's global platform had approximately $546 billion of assets under management, with operations across North America, South America, Europe, Asia Pacific and the Middle East. For more information, please visit
Business Journals
an hour ago
- Business Journals
3 simple steps for employers to lower health care costs and ensure better employee care
It's no secret that the current health care system is unsustainable. Nearly half of Americans receive health care coverage through their employer and over the past two decades, employer-sponsored health care costs have risen by over 200%. Many businesses can no longer front the costs — and the burden is being shifted onto employees. The result? Health care has become unaffordable for many working Americans — for some employees cost shifting has made engaging care unaffordable and 40% of American adults are struggling with medical debt — a shockingly high number. Despite this astronomical rise in cost, most brokers and benefits consultants haven't changed the solutions they present to clients in decades. In our experience, only about 5-10% of brokers are offering their clients innovative alternatives and even fewer have fully embraced a different approach, leading to poor implementation and support when they do try something new. The reality is that health care operates as an inefficient market. Unlike most industries, higher costs do not necessarily equate to higher quality care — in fact, it can often be the opposite. We believe that by being proactive, transparent and strategic, employers can reverse this trend by reducing costs while ensuring their employees receive top-quality care. However, achieving transformational results demands a completely different approach. The four of us have spent years in this industry and have tailored a unique approach that enables us to achieve superior results. We've seen what works and what doesn't and the ineffective options continually peddled to employers. That's why we've joined forces to help employers to take control of their health care spend and save real money. Our approach We don't believe in a one-size-fits all health plans and we partner with HR leaders to bring their health care strategy to life while directly administering the change. This includes educating employees on what they need to know to make the most of their benefits. When you show people exactly how they can receive better care at a lower price, everyone wins. Our model is built on three pillars: education, pharmacy platform and Medicare Plus. Education: We empower members to navigate the health care system effectively and steer them towards high quality and cost-effective options. Navigating the health care system is hard and we take a hands-on approach, which helps members understand their choices and make informed decisions. This extra effort improves health outcomes while ensuring the best experience possible. According to publicly available data compiled by Image360, CT scans in Tampa, Florida, are typically billed between $4,500 and $9,700. Even after PPO discounts, health plan members and businesses still pay $2,200 to $4,800. The problem is, there's little transparency in pricing and high cost doesn't guarantee high quality. Imagine360 changes that. With Imagine360, the average cost for the same CT scan at the same facility drops to under $200. This translates to significant savings for the employee and the business. Pharmacy platform: Pharmacy spend is the fastest-growing expense when it comes to a health plan. Traditional solutions often lack transparency and instead function as profit centers. We craft innovative solutions to manage pharmacy costs, ensuring that members have access to affordable medications without compromising on quality. Medicare Plus: We provide a thoughtful alternative to conventional PPOs. This model offers robust coverage at significantly lower costs by anchoring reimbursements to fair, Medicare-based rates. The above approach collectively has proven to cut costs by nearly 25% on average. Through this approach, we've reduced the cost of health care so drastically that some clients now offer no-cost health care to all of their employees. At a time when most companies are forcing employees to pay upwards of thousands of dollars per month on health insurance premiums, our clients pick up the full cost of premiums for their employees. This difference is life-changing for many families. By adopting a three-pillar approach to health care benefits, these businesses have become highly sought-after employers in their communities. And it's not just beneficial for employees — it's advantageous for the health plan as well. When health care premiums are overpriced, only the highest utilizers enroll, which makes sense; you would only pay thousands of dollars a month in premiums if you anticipated high health care expenses. However, when coverage is affordable and well-structured, everyone participates, creating a healthier, more predictable and sustainable plan. If this sounds too good to be true, you're not alone. One employer came to us frustrated and skeptical. Every broker had pitched the same traditional solutions, none of which solved their problem. Their chief financial officer knew that if they could not control hospital claims costs, the business would be in trouble. We introduced Medicare Plus pricing as a strategic solution. We helped manage the learning curve for the first few months — but once leadership committed to the solution, the plan started working. Three years in, premiums, deductibles and copays have all dropped. Employees are getting better coverage, and the company has even added new benefits — while most of their peers are cutting back. Using an independent TPA Working with an independent third-party administrator (TPA) opens the door to a different and better playbook. Yes, it takes more work upfront — more education, communication, teamwork — but the payoff is worth it: a more flexible employee benefits solution that can lead to better care, lower costs, and long-term consistency. No more carrier swaps or yearly overhauls. We currently support 25 clients on this platform. With dedicated service teams, personalized enrollment education and long-term strategies, we help employers innovate — without impacting employee satisfaction. The result is a smoother, more positive experience. The road ahead We're all fighting the same fight: pushing back against a system that hides cost, limits choices, wastes money and is driving people to choose little or no coverage due to cost. But it doesn't have to be this way. With a three-pronged approach including employee education, pharmacy and Medicare Plus pricing, we're helping employers take back control of their health care costs. By putting people first and staying committed to value-based solutions, employers and brokers can finally break free from the old playbook — and build something better. McGriff is a Marsh & McLennan Agency LLC Company. Our solutions include commercial property and casualty, corporate bonding and surety, cyber, executive risk, management and professional liability, captives and alternative risk transfer programs, employee benefits, small business and personal lines insurance.
